| Archived Events |
|---|
BIO-Europe Spring
Mar 8, 2010 -
Mar 10, 2010
Speaker: Ken Mohler, PhD, Chief Scientific Officer
|
|
Barcelona, Spain
Conference web site -- http://www.ebdgroup.com/bes/program.htm
|
IBC's Recombinant Protein & Complex Biologic Development and Production Conference
Mar 5, 2010
Speaker: Tony Siadak, Ph.D., Trubion Scientist
|
|
TRU-ADhanCe IBC Presentation March 3-5 2010
1.3 MB PDF
Carlsbad, CA
ABSTRACT:
Utilization of TRU-ADhanCe™ Technology to Significantly Enhance the ADCC Potency of Immunoglobulin Fc-Bearing Molecules
TRU-ADhanCe™ is a broadly applicable manufacturing technology designed to markedly augment the antibody-dependent cellular cytotoxicity (ADCC) of active Fc-containing molecules. With the simple addition of the glycosidase inhibitor castanospermine during the cell culture stage, core-fucose of Fc glycans is significantly reduced resulting in enhanced ADCC activity, while protein production is maintained at high level. This presentation will provide an overview of the technology and a case study of its application to a Small Modular Immunopharmaceutical (SMIP)™ molecule.
|
IBC's Recombinant Protein & Complex Biologic Development and Production Conference
Mar 5, 2010
Speaker: John W. Blankenship, Ph.D., Trubion Scientist
|
|
Trubion IBC Presentation
708.4 KB PDF
Carlsbad, CA
ABSTRACT:
Beyond SMIPs™: The Development of Small Multi-Specific Immunotherapeutics
Engineering specificity for more than one therapeutic target into antibodies has been challenging. We have developed several technologies, including the Scorpion™ platform, to bind more than one target simultaneously, whether soluble ligands or cell surface receptors. These scaffolds retain the advantages of antibodies - high affinity, lack of immunogenicity, long plasma halflife - and are amenable to large-scale production and purification.
|
Keystone Scientific Meeting
Feb 27, 2010 -
Mar 4, 2010
Speaker: Catherine McMahan
|
|
Breckenridge, CO
ABSTRACT TITLE: Small Modular ImmunoPharmaceutical (SMIP)
Molecules Drive Strong Calcium Signals, As Well As
Increased Blocking Of T Cell Activation
|
OneMedForum 2010
Jan 12, 2010 8:30 AM PT
Speaker: Michelle Burris, Senior Vice President and Chief Operating Officer
|
|
Sir Francis Drake Hotel
San Francisco
|
ASH 2009 Annual Meeting
Dec 5, 2009 -
Dec 8, 2009
|
|
TRU-016 P1 ASH Poster 12-7-09
479.0 KB PDF
TRU-ADhanCe 2009 ASH Poster.pdf
1.5 MB PDF
67.8 KB PDF
TRU-016 Phase 1 and preclinical data will be presented at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana. The presentations will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating the effect of Trubion's Tru-ADhanCe™ technology in promoting enhanced natural killer cell mediated cytotoxicity against primary CLL cells. TRU-016 is Trubion's novel CD37-targeted therapy for the treatment of B-cell malignancies and is being developed in collaboration with Facet Biotech Corporation.
|
Trubion Third Quarter 2009 Earnings Conference Call
Nov 5, 2009 2:00 PM PT
|
|
|
Next Generation Protein Therapeutics Conference
Nov 3, 2009 -
Nov 5, 2009
Speaker: Ken Mohler, PhD, Co-founder and SVP, R&D
|
|
|
BIO Investor Forum: Panel Presentation
Oct 29, 2009 2:00 PM AKT
Speaker: Peter Thompson, MD, FACP, President, CEO and Chairman
|
|
Palace Hotel, San Francisco
Resisting the Enemy Within - Keeping Score on the War Against Autoimmune Disease
http://investorforum.bio.org/opencms/bif/2009/Program/AutoImmune.html
Arthritis, lupus, gout and other debilitating inflammatory conditions are chronic autoimmune illnesses characterized by an immune system that has become misdirected. An estimated 43 million people in the United States alone develop autoimmune rheumatic conditions. By 2020, there will be 60 million diagnosed. Unfortunately, many patients do not fully respond to available treatments and those treatments that are available are known to cause further complications, such as PML. With the discovery of new molecular targets and pathways, companies are advancing new classes of medicines for autoimmune inflammatory diseases, including oral kinase inhibitors in RA and monoclonal antibodies in lupus. The current pipeline may hold the answer for millions of patients. Companies with late-stage compounds for arthritis and inflammatory diseases, key opinion leaders and advocates will provide insights on experimental new autoimmune therapies, clinical need and application and the development landscape.
Moderator:
Liana Moussatos, Ph.D, Senior Healthcare Research Analyst, Wedbush PacGrow Life Sciences
Panelists:
C. Garrison Fathman, MD, Chief Division of Immunology and Rheumatology, Stanford University School of Medicine,
John A. Hardin, MD, Chief Scientific Officer, Arthritis Foundation,
Sandra C. Raymond, President and CEO, Lupus Foundation of America,
Alan M. Solinger, MD, FACP, FACR, Vice President of Clinical Immunology, XOMA
Peter A. Thompson, MD, FACP, President & CEO, Trubion Pharmaceuticals
|
ACR 2009 Annual Meeting
Oct 18, 2009
Speaker: Scott Stromatt, MD, Trubion CMO
|
|
ACR 2009 TRU-015 R2 RA Poster
727.7 KB PDF
Abstract: 403 - Sustained Safety and Efficacy of TRU-015 with Continued Retreatment of Rheumatoid Arthritis Subjects Following a Phase 2B Study
|
IBC's 4th Annual Beyond Antibodies Conference
Sep 21, 2009 -
Sep 23, 2009
Speaker: Alan Lofquist, Associate Director, Research
|
|
|
Americas Anitbody Congress 2009
Sep 21, 2009 -
Sep 23, 2009
Speaker: Ken Mohler, PhD, Trubion Co-founder and SVP, R&D
|
|
Washington, D.C.
Panel: Next generation protein types
|
Morgan Stanley Global Healthcare Conference
Sep 14, 2009 8:00 AM ET
|
|
|
Trubion Second Quarter 2009 Earnings Conference Call
Aug 6, 2009 2:00 PM PT
|
|
|
EULAR 2009: TRU-015 Retreatment Data Presentation
Jun 11, 2009
Speaker: Scott Stromatt, Chief Medical Officer, Trubion
|
|
|
8th Annual Needham Life Sciences Conference
Jun 10, 2009 2:00 PM ET
|
|
Dr. Ken Mohler, co-founder and Senior Vice President of research and development, and Michelle Burris, Senior Vice President and Chief Financial Officer, are scheduled to present.
|
Three TRU-016 Presentations Accepted for Presentation at the 2009 ASCO Annual Meeting
May 31, 2009
|
|
TRU-016 Phase 1 ASCO 2009 Poster
289.5 KB PDF
TRU-016 ASCO 2009 NHL Poster.pdf
1.5 MB PDF
TRU-016 ASCO-2009 Apoptosis Poster 3035.pdf
579.4 KB PDF
Orlando, FL
Phase 1: Encouraging Results Observed in CLL Patients Treated With Low Doses of TRU-016
Preclinical Efficacy: TRU-016 is Additive or Synergistic in Combination with Established Therapeutics
Preclinical Mechanism Apoptosis in CLL Cells Occurs Via Distinct Mechanism Compared With Other Therapeutics
Complete abstracts are available on ASCO's web site at:
http://www.asco.org/ASCOv2/Meetings/ASCO+Annual+Meeting
|
Trubion First Quarter 2009 Earnings Conference Call
May 7, 2009 2:00 PM PT
|
|
|
Trubion Presents SCORPION Data at 2009 AACR Annual Meeting
Apr 22, 2009 8:00 AM -
12:00 PM
Speaker: John W. Blankenship
|
|
2.4 MB PDF
Preclinical Poster Presentation: "CD79BxDR SCORPION molecule -a single chain, bispecific immunotherapeutic with potent in vitro activity against B cell lymphoma"
|
Invest Northwest Investor Conference
Mar 18, 2009
Speaker: Michelle Burris, CFO and SVP, Trubion
|
|
Bell Harbor Convention Center
Seattle
|
Trubion Fourth Quarter and Year-End 2008 Earnings Conference Call
Mar 12, 2009 2:00 PM PT
|
|
|
BIO CEO & Investor Conference
Feb 10, 2009
Speaker: Peter Thompson, MD, FACP, CEO and Chairman, Trubion
|
|
|
Lazard Capital Management 5th Annual Investor Healthcare Conference
Nov 18, 2008
Speaker: Peter Thompson, MD, FACP, President, CEO and Chairman
|
|
|
Trubion Third Quarter 2008 Earnings Conference Call
Nov 10, 2008 2:00 PM PT
|
|
|
Rodman & Renshaw 10th Annual Investor Healthcare Conference
Nov 10, 2008 -
Nov 12, 2008
Speaker: Michelle Burris, CFO, SVP
|
|
|
ACR 2008 Annual Meeting
Oct 26, 2008 9:00 AM -
11:00 AM PT
|
|
1.2 MB PDF
Presentation: 374 - TRU-015 Administered Every 24 Weeks for 2 Years is Well Tolerated and Maintains Consistent Pharmacodynamic Effects in Rheumatoid Arthritis Patients
http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2173&sKey=dce5e7b7-ccd3-441c-97b8-23a76a10390d&cKey=966b267e-79a4-4f45-979c-f895e78dc77c
|
2008 American College of Clinical Pharmacology Annual Meeting
Sep 14, 2008 -
Sep 16, 2008
|
|
524.3 KB PDF
TRU-015 for RA PK Data Presentation
|
Morgan Stanley Global Healthcare Unplugged Conference
Sep 9, 2008 4:30 PM ET
Speaker: Peter Thompson, MD, FACP
|
|
Grand Hyatt New York
Dr. Peter Thompson, President, Chief Executive Officer and Chairman, and Dr. Scott C. Stromatt, newly appointed Senior Vice President and Chief Medical Officer, are scheduled to present.
|
Trubion Second Quarter 2008 Earnings Conference Call
Aug 7, 2008 2:00 PM PT
|
|
|
Bank of America 2008 Specialty Pharmaceuticals Conference
Aug 7, 2008 8:45 AM ET
Speaker: Dr. Peter A. Thompson, President, CEO and Chairman
|
|
Southampton Inn
Long Island, NY
|
2008 PDA/EBE Conference on Biopharmaceutical Development and Manufacturing
Jun 24, 2008 -
Jun 25, 2008
Speaker: Vijay Yabannavar, Ph.D., VP, Process Development and Manufacturing
|
|
|
Needham 7th Annual Biotechnology & Medical Technology Conference
Jun 12, 2008 10:00 AM ET
Speaker: Ken Mohler, PhD, Co-founder, Senior Vice President of Research & Development, and Michelle Burris, Senior Vice President and Chief Financial Officer
|
|
New York Palace Hotel, NY, NY
|
Trubion Presents Positive Pre-clinical TRU-016 Data at ASCO
Jun 2, 2008
|
|
|
Bank of America 2008 Health Care Conference
May 13, 2008 1:20 PM PT
Speaker: Michelle Burris, Senior Vice President and Chief Financial Officer
|
|
The Four Seasons Hotel, Las Vegas, NV
|
Trubion First Quarter 2008 Earnings Conference Call
May 8, 2008 2:00 PM PT
|
|
|
Morgan Stanley Global Healthcare Unplugged Conference
Apr 30, 2008 9:50 AM ET
Speaker: Peter Thompson, MD, FACP, President, CEO and Chairman
|
|
The Ritz-Carlton, Key Biscayne, FL
|
2008 Gene Therapy of Arthritis and Related Disorders Annual Meeting
Apr 29, 2008
Speaker: Ken Mohler, Ph.D, SVP R&D Trubion
|
|
|
Cell Culture Engineering XI Conference
Apr 13, 2008
Speaker: Vijay Yabannavar, VP, Manufacturing
|
|
|
Invest Northwest CEO & Investor Forum
Mar 18, 2008 11:20 AM PT
Speaker: Ken Mohler, PhD, Co-founder, Senior Vice President of Research & Development
|
|
Bell Harbor International Conference Center, Seattle, WA
|
Trubion Fourth Quarter 2007 Earnings Conference Call
Mar 13, 2008 2:00 PM PT
|
|
|
Trubion Second Quarter 2007 Earnings Conference Call
Aug 13, 2007 2:00 PM PT
|
|
|
Investor Presentation
April 2007
|
|
|
